Developing RNAi Therapeutics for Treatment of Cancer & Fibrosis Diseases

READ MORE

LATEST NEWS

November 1, 2019
Sirnaomics to Present Preclinical STP705 Data Suggesting Reduction in Liver Fibrosis at AASLD Liver Meeting Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE
October 25, 2019
Sirnaomics Leadership to Speak at 7th China Renaissance Healthcare and Life Sciences Summit GAITHERSBURG, MD., Oct. 24, 2019 /PRNewswire/ — Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and... READ MORE
October 19, 2019
Sirnaomics’ President and CEO Patrick Lu Gives Keynote Address at the 7th RNAi China Conference Sirnaomics Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of RNAi therapeutics... READ MORE
June 3, 2019
Sirnaomics Counts on New RNA Technology to Fuel Wide-Ranging Cancer & Fibrosis Pipeline While some RNA technology companies are still exploring the accompanying science, Sirnaomics, based in Gaithersburg... READ MORE
May 28, 2019
Sirnaomics Appoints Allan L. Shaw as Chief Financial Officer Mr. Shaw is a highly regarded biopharmaceutical executive and board member with more than twenty... READ MORE

Science

Our team uses a consistent, validated approach to develop novel siRNA based therapeutics for significant markets with high unmet clinical need. Using a proprietary algorithm for siRNA sequence prediction against known gene targets we can rapidly identify siRNAs for use against traditionally "non-drugable" targets ...

Read More

Pipeline

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas...

Read More
U.S.A  •  China
© 2007-2019 by Sirnaomics, Inc.
Contact